Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: daifotis a. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835
Esophagitis associated with the use of alendronate.
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK. de Groen PC, et al. Among authors: daifotis a. N Engl J Med. 1996 Oct 3;335(14):1016-21. doi: 10.1056/NEJM199610033351403. N Engl J Med. 1996. PMID: 8793925 Free article. Review.
The clinical tolerability profile of alendronate.
Watts N, Freedholm D, Daifotis A. Watts N, et al. Among authors: daifotis a. Int J Clin Pract Suppl. 1999 Apr;101:51-61. Int J Clin Pract Suppl. 1999. PMID: 12669741 Review.
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE. Ravn P, et al. Among authors: daifotis a. J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7. doi: 10.1210/jcem.85.4.6549. J Clin Endocrinol Metab. 2000. PMID: 10770187 Clinical Trial.
Weekly oral alendronic Acid in male osteoporosis.
Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A. Miller PD, et al. Among authors: daifotis a. Clin Drug Investig. 2004;24(6):333-41. doi: 10.2165/00044011-200424060-00003. Clin Drug Investig. 2004. PMID: 17516720
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Saag KG, et al. Among authors: daifotis ag. N Engl J Med. 1998 Jul 30;339(5):292-9. doi: 10.1056/NEJM199807303390502. N Engl J Med. 1998. PMID: 9682041 Free article. Clinical Trial.
28 results